CROMBIE REIT ANNOUNCES MAY 2025 MONTHLY DISTRIBUTION
The distribution will be payable on June 13, 2025, to Unitholders of record as at May 31, 2025.
About Crombie REIT
Crombie invests in real estate with a vision of enriching communities together by building spaces and value today that leave a positive impact on tomorrow. As one of the country's leading owners, operators, and developers of quality real estate assets, Crombie's portfolio primarily includes grocery-anchored retail, retail-related industrial, and mixed-use residential properties. As at March 31, 2025, our portfolio contained 303 properties comprising approximately 18.8 million square feet, inclusive of joint ventures at Crombie's share, and a significant pipeline of future development projects. Learn more at www.crombie.ca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
2 hours ago
- National Post
Almonty Industries Announces 1-for-1.5 Share Consolidation in Anticipation of Potential Nasdaq Listing
Article content TORONTO — Almonty Industries Inc. (' Almonty ' or the ' Company ') (TSX: AII) (ASX: AII) (OTCQX: ALMTF) (Frankfurt: ALI), a leading global producer of tungsten concentrate, is pleased to announce that it has filed articles of amendment to consolidate its issued and outstanding common shares (' Shares ') on the basis of one (1) post-consolidation Share for every one and a half (1.5) pre-consolidation Shares (the ' Consolidation '). The Consolidation was approved by shareholders of the Company (' Shareholders ') at the annual general and special meeting of Shareholders held on April 30, 2025. The Company is implementing the Consolidation for the reasons disclosed in the management information circular dated March 21, 2025 (the ' Circular '), including to facilitate a potential Nasdaq listing. Article content The Company expects that the Shares will commence trading on a post-Consolidation basis at the start of trading on July 7, 2025 on the Toronto Stock Exchange (the ' TSX '), subject to receipt of necessary exchange approvals. Following the Consolidation, the new CUSIP number for the Shares will be 020398707 and the new ISIN number will be CA0203987072. Article content Trading on the Australian Securities Exchange in CHESS Depositary Interests (' CDIs ') representing the Shares will commence on a deferred settlement basis at the start of trading on July 8, 2025. Trading in post-Consolidation CDIs on a normal settlement basis will commence at the start of trading on July 17, 2025. The Company expects to have approximately 195,860,844 Shares (including CDIs) outstanding following the Consolidation, subject to rounding for any fractional Shares. Article content No fractional Shares will be issued in connection with the Consolidation. In the event that a Shareholder would otherwise be entitled to receive a fractional Share upon the occurrence of the Consolidation, such fraction will be rounded down to the nearest whole number. All stock options, warrants and other rights to purchase or otherwise acquire Shares shall be adjusted to reflect the Consolidation in accordance with the terms and conditions governing such convertible securities. Article content Almonty's transfer agent, Computershare Investor Services Inc. (' Computershare '), will mail a letter of transmittal to registered Shareholders of the Company providing instructions on how to exchange existing Share certificates or direct registration system (DRS) statements. A sample letter of transmittal is also available on the Company's profile on SEDAR+. Non-registered Shareholders who hold their Shares through a bank, broker or other nominee and who have questions regarding how the Consolidation will be processed should contact their nominee. Until surrendered to Computershare, each Share certificate or other evidence representing pre-Consolidation Shares will be deemed for all purposes to represent the number of post-Consolidation Shares to which the registered Shareholder is entitled as a result of the Consolidation. Article content New holding statements will be dispatched to holders of CDIs on a post-Consolidation basis between July 10, 2025 and July, 16 2025. Article content The Consolidation remains subject to the final approval of the TSX. Additional details regarding the Consolidation can be found in the Circular, which is available under the Company's profile on SEDAR+ at Article content About Almonty Article content Almonty is a diversified and experienced global producer of tungsten concentrate in conflict-free regions. The Company is currently mining, processing and shipping tungsten concentrate from its Panasqueira Mine in Portugal. Its Sangdong Mine in Gangwon Province, South Korea is currently under construction. The Sangdong Mine was historically one of the largest tungsten mines in the world and one of the few long-life, high-grade tungsten deposits outside of China. Almonty also has a significant molybdenum resource on a separate property adjacent to the tungsten orebody at the Sangdong Mine. Additional development projects include the Valtreixal Project in northwestern Spain and Los Santos Mine in western Spain. Further information about Almonty's activities may be found at and under Almonty's profile at and Legal Notice Article content The release, publication, or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published, or distributed should inform themselves about and observe such restrictions. Article content Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. Article content Cautionary Note Regarding Forward-Looking Information Article content This news release contains 'forward-looking statements' and 'forward-looking information' within the meaning of applicable securities laws. Article content All statements, other than statements of present or historical facts, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are typically identified by words such as 'plan', 'development', 'growth', 'continued', 'intentions', 'expectations', 'emerging', 'evolving', 'strategy', 'opportunities', 'anticipated', 'trends', 'potential', 'outlook', 'ability', 'additional', 'on track', 'prospects', 'viability', 'estimated', 'reaches', 'enhancing', 'strengthen', 'target', 'believes', 'next steps' or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements concerning the Consolidation, the timing of trading of the Shares and CDIs on a post-Consolidation basis, the number of issued and outstanding Shares following completion of the Consolidation, the receipt of final approval for the Consolidation from the TSX, the delivery of letters of transmittal, the treatment of convertible securities in connection with the Consolidation, and a potential Nasdaq listing. Article content Forward-looking statements are based upon certain assumptions and other important factors that, if untrue, could cause actual results to be materially different from future results expressed or implied by such statements. There can be no assurance that forward-looking statements will prove to be accurate. Key assumptions upon which the Company's forward-looking information is based include, without limitation, the timely delivery of letters of transmittal and the ability of the Company to obtain final approval of the Consolidation from the TSX and to meet Nasdaq listing requirements. Article content Forward-looking statements are also subject to risks and uncertainties facing the Company's business, including, without limitation, the impact of general economic conditions, industry conditions, and dependence on regulatory approvals. Any of these risks could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. Readers should consider reviewing the detailed risk discussion in the Company's most recent Annual Information Form and the Amended Management Discussion and Analysis for the three months ended March 31, 2025 filed on SEDAR+, for a fuller understanding of the risks and uncertainties that affect the Company's business and operations. Article content Although Almonty has attempted to identify important factors that could cause actual results, level of activity, performance or achievements to differ materially from those contained in forward-looking statements, there may be other factors that cause results, level of activity, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and even if events or results described in the forward-looking statements are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, Almonty. Accordingly, readers should not place undue reliance on forward-looking statements and are cautioned that actual outcomes may vary. Article content Investors are cautioned against attributing undue certainty to forward-looking statements. Almonty cautions that the foregoing list of material factors is not exhaustive. When relying on Almonty's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. Article content THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF ALMONTY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD- LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE ALMONTY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS. Article content Article content Article content Contacts Article content Company Contact Article content Article content Lewis Black Article content Article content Chairman, President & CEO Article content Article content (647) 438-9766 Article content Article content Article content Article content
Cision Canada
4 hours ago
- Cision Canada
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services. The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide. "Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan. With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes. Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility. "We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets. Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: [email protected] About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Cision Canada
7 hours ago
- Cision Canada
World-Leading Breakthrough! Risen Energy's HJT Modules Hit Average 740Wp Mass Production with Record 26.61% Cell Efficiency
NINGBO, China, July 2, 2025 /CNW/ -- A milestone in global heterojunction (HJT) photovoltaic technology! Risen Energy Co., Ltd. (Stock Code: 300118) today announced its self-developed Hyper-ion HJT modules have achieved a groundbreaking 740Wp average mass-production power, setting a new industry efficiency benchmark. With certified cell conversion efficiency of 26.61%, this innovation demonstrates immediate R&D-to-production integration. This breakthrough cements Risen Energy's leadership in high-efficiency PV industrialization. Core Innovations: Patent-Protected Tech & Cost-Performance Revolution Leveraging National Key Research and Developement Program, Risen Energy's proprietary technologies deliver structural optimization and drastic cost reduction while maintaining peak efficiency: Metallization Upgrade: Silver consumption slashed to 5mg/W (↓37.5% vs. TOPCon), driving non-silicon cost reduction via stencil printing. Low CTM Loss Encapsulation: Module CTM (Cell-To-Module) loss minimized to 1.8% with cell breakage-rates under 0.03%, enabling high-yield manufacturing. Dual Advantages: High Energy Yield & Ultra-Low Carbon The 740W Hyper-ion module's -0.24%/°C temperature coefficient and 90% bifaciality delivered 4.09% higher power output than TOPCon at SGS Saudi Arabia's test site. Peak monthly gains hit 6.04% in August, proving its "higher heat, higher yield" reliability. Per 100MW project, this translates to: +3 million kWh annual power generation 2,880 tons CO₂ reduction Carbon footprint as low as 376.5kg eq CO₂/kWc Global Market Momentum As the prime solution for utility-scale, commercial/industrial, and high-temperature projects, Risen Hyper-ion Pro series HJT modules dominate: 9GW+ 2025 HJT-specific tenders in China (led by state-owned giants like China Green Dev./CGN etc.) Expansion to 50+ countries across Middle East/Southeast Asia 6%+ verified energy gain in Saudi/UAE high-irradiation regions, slashing LCOE. Vision from Leadership Dr. Yang Pochuan, Dean of Risen Global PV Research Institute: "We're targeting >27% cell efficiency and 790W+ monocrystalline modules within 3 years. Our perovskite tandem tech will enable 850Wp+ mass production by 2028, advancing the world's net-zero transition with 'China Solutions'. SOURCE Risen Energy Co., Ltd
